prof.dr. M.J. IJzerman (Maarten)

Maarten J. IJzerman is professor and head of Cancer Health Services Research in the University of Melbourne and Peter MacCallum Cancer Centre and a part-time professor in the University of Twente's TechMed Centre. His international work is focussed on the health economics and health services implications of personalised medicine, including drug treatment sequencing and the use of complex genomic sequencing. He develops and applies new methods for value assessment of medical technologies, in particular molecular diagnostics for precision oncology. He is a pioneer in the field of early Health Technology Assessment, supporting the clinical translation of medical innovation by modelling their health and economic impact in an early stage of development.

Before moving to Melbourne in 2018, he was the founding chair of the Department of Health Technology and Services Research (2007-2015), director of education for Health Sciences program (2007-2011), acting director of the MIRA institute for Biomedical Engineering and Technical Medicine (2013-2014) and vice-dean for Health & Biomedical Technology in the Faculty of Science and Technology (2015-2017). Before then, he worked as a visiting scholar in different academic centres in the USA and Canada and was the scientific director of Roessingh Research and Development (2000-2007).

Maarten has supervised many MSc and PhD students in several UT degree programs (TM, HS, BME and IEM) and is a mentor to early-to-mid career academics globally.

Social Sciences

# Cancer
# Health Economics

Medicine & Life Sciences

# Cost-Benefit Analysis
# Costs And Cost Analysis
# Decision Support Techniques
# Delivery Of Health Care
# Economics
# Health

Faculty of Behavioural, Management and Social Sciences (BMS), Health Technology & Services Research (HTSR)

Erasmus University Rotterdam
Academic, fulltime position
Laboratorium Microbiologie
Raad van Toezicht
University of Melbourne
Academic research

Vu, M., Degeling, K., Thompson, E. R., Blombery, P., Westerman, D. , & IJzerman, M. J. (2024). Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia. Applied health economics and health policy, 22, 107-122. https://doi.org/10.1007/s40258-023-00826-4

Behr, C. , Koffijberg, H. , IJzerman, M., Kauczor, H. U., Revel, M. P., Silva, M., von Stackelberg, O. , van Til, J., & Vliegenthart, R. (2023). Willingness to participate in combination screening for lung cancer, chronic obstructive pulmonary disease and cardiovascular disease in four European countries. European radiology. Advance online publication. https://doi.org/10.1007/s00330-023-10474-w

Glewis, S., Krishnasamy, M., Lingaratnam, S., Harris, S., Underhill, C., Georgiou, C., Warren, M., Campbell, R. , IJzerman, M., Fagery, M., Campbell, I., Martin, J. H., Tie, J., Alexander, M., & Michael, M. (2023). Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey. Clinical and Translational Science, 16(12), 2700-2708. https://doi.org/10.1111/cts.13664

Field, K. M., Andrew Rosenthal, M., Gillett, P. , & IJzerman, M. (2023). Assessing neuro-oncology clinical trial impact and value: Testing a novel multi-criteria decision analysis app. Journal of Clinical Neuroscience, 118, 70-78. https://doi.org/10.1016/j.jocn.2023.07.024

Gillett, P., Mahar, R. K., Tran, N. R., Rosenthal, M. , & IJzerman, M. (2023). Developing and validating a multi-criteria decision analytic tool to assess the value of cancer clinical trials: evaluating cancer clinical trial value. Cost effectiveness and resource allocation, 21(1), Article 87. https://doi.org/10.1186/s12962-023-00496-y

Khorshidi, H. A., Marshall, D., Goranitis, I., Schroeder, B. , & IJzerman, M. (2023). System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model. Expert Review of Pharmacoeconomics and Outcomes Research. Advance online publication. https://doi.org/10.1080/14737167.2023.2267764

Drosdowsky, A., Lamb, K. E., Karahalios, A., Bergin, R. J., Milley, K., Boyd, L. , IJzerman, M. J., & Emery, J. D. (2023). The effect of time before diagnosis and treatment on colorectal cancer outcomes: systematic review and dose–response meta-analysis. British journal of cancer, 129(6), 993-1006. https://doi.org/10.1038/s41416-023-02377-w

Ven, M. V. D. , Koffijberg, H. , Retèl, V. P. J. , Harten, W. H. V. , & IJzerman, M. J. (2023). Dynamic Simulation Modeling to Analyze the Impact of Whole Genome Sequencing National Implementation Scenarios in Lung cancer on Time-to-Treatment, Costs and Patient Demand. MedRxiv. https://doi.org/10.1101/2023.11.10.23298371

Berghuis, A. M. S. , Koffijberg, H. , Pouwels, X. G. L. V., Berger, F., Alix-Panabières, C., Jacot, W., Pierga, J. Y., Bidard, F. C. , & IJzerman, M. J. (2023). Cost-effectiveness of CTC guided chemo- or endocrine therapy in ER+ HER2- metastatic breast cancer – results from a randomized controlled multicenter trial. https://doi.org/10.1101/2023.10.09.23296711

van Delft, F. A., Schuurbiers, M. M. F., Muller, M., Burgers, S., van Rossum, H. H. , IJzerman, M. J., van den Heuvel, M. M. , & Koffijberg, H. (2023). Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer. Tumor Biology. https://doi.org/10.3233/TUB-220022

See all research output of this employee

View my profile

I am committed to teaching in graduate programs in the University of Twente and Melbourne as well as international short-courses for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Master

Industrial Engineering and Management

Courses in the current academic year are added at the moment they are finalised in the Osiris system. Therefore it is possible that the list is not yet complete for the whole academic year.

193650999 - Masters Assignment

https://www.utoday.nl/covid-19-research-at-ut/68467/delays-in-cancer-treatments-due-to-corona-crisis
https://www.utwente.nl/en/news/2018/3/39094/maarten-ijzerman-to-lead-world-class-cancer-research-program-in-melbourne

Tweets by maartenijzerman

+31534893684

+61385598585

+31534897475 (if no answer)

m.j.ijzerman@utwente.nl

maarten.ijzerman@unimelb.edu.au